In the spirit of transparency, and in compliance with industry guidelines, ALK shares details of its clinical trials.
As a responsible, ethical, research-driven pharmaceutical company, we support the sharing of clinical trial information to help doctors and scientists further their understanding of allergic disease and potential treatment options.
At the same time, and in accordance with industry guidelines, we are also committed to safeguarding the privacy of patients, the integrity of regulatory authorities, and the intellectual property of trial sponsors.
A range of ALK policies and documents outline our approach to sharing clinical trials data and how to request access.
ALK's policy for data sharing can be downloaded here
In accordance with EFPIA’s and PhRMA´s “Principles for Responsible Clinical Trial Data Sharing” guidelines, ALK is committed to responsible sharing of clinical trial data in a manner that safeguards the privacy of patients, respects the integrity of national regulatory systems, and protects the intellectual property of the sponsor.
